What's in AEterna Zentaris's pipeline?

AEterna Zentaris has 7 drugs in our index: 1 marketed, 0 filed, 6 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with AEterna Zentaris's portfolio?

Top competitors by shared drug class: Jiangsu HengRui Medicine Co., Ltd., Cassiopea SpA, Instituto de Investigacion Sanitaria La Fe, El Shatby University Hospital for Obstetrics and Gynecology, Eugonia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aeterna-zentaris.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

AEterna Zentaris — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AEterna Zentaris pipeline: 1 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Macrilen	MACIMORELIN	marketed	Growth Hormone Secretagogue Receptor Agonist	Growth hormone secretagogue receptor type 1	Other	2017-01-01
Cetrorelix Pamoate	Cetrorelix Pamoate	phase 3	GnRH antagonist	GnRH receptor	Oncology; Reproductive Health
AEZS-130 (formerly ARD-07)	AEZS-130 (formerly ARD-07)	phase 3	Androgen receptor antagonist	Androgen receptor (AR)	Oncology
AEZS-108 / zoptarelin doxorubicin	AEZS-108 / zoptarelin doxorubicin	phase 3	Targeted chemotherapy conjugate / GnRH receptor-targeted cytotoxic	GnRH receptor (GnRHR)	Oncology
L-ARG+GHRH	L-ARG+GHRH	phase 3	Growth hormone secretagogue / amino acid combination	GHRH receptor (GHRHR); nitric oxide pathway	Endocrinology / Metabolic disorders
shark cartilage extract AE-941	shark cartilage extract AE-941	phase 3			Oncology
Cetrorelix 78+78	Cetrorelix 78+78	phase 3	GnRH antagonist	GnRH receptor	Oncology; Reproductive/Endocrinology

Therapeutic area mix

Oncology · 3
Endocrinology / Metabolic disorders · 1
Oncology; Reproductive Health · 1
Oncology; Reproductive/Endocrinology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Cassiopea SpA · 1 shared drug class
Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
Eugonia · 1 shared drug class
Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 shared drug class
EMD Serono · 1 shared drug class
CHU de Quebec-Universite Laval · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AEterna Zentaris:

Cite this brief

Drug Landscape (2026). AEterna Zentaris — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aeterna-zentaris. Accessed 2026-06-10.